Update shared on 11 Nov 2025
Fair value Increased 0.95%Analysts have raised their price target for Smith & Nephew slightly. The target has increased from $14.23 to $14.37, citing updated financial assumptions including modest improvements in profit margin and a slight increase in the projected discount rate.
What's in the News
- Smith & Nephew maintained its earnings guidance for 2025, projecting trading profit margin growth to between 19.0% and 20%. The company also anticipates a net tariff impact of $15 million to $20 million. (Corporate Guidance)
- Findings from a landmark study of single-use negative pressure wound therapy (sNPWT) devices showed that Smith+Nephew's PICO sNPWT device significantly reduced risk of wound dehiscence, length of hospital stay, and healthcare costs for orthopedic and cardiovascular surgery patients compared to Prevena. (Product-Related Announcements)
- Sectra expanded its 3D pre-operative planning tools for trauma surgery to include Smith+Nephew templates. This enables improved surgeon planning, operational efficiency, and patient outcomes. (Client Announcements)
- New evidence on the REGENETEN Bioinductive Implant highlighted its effectiveness in reducing rotator cuff re-tear rates and noted that its indications have now expanded to include extra-articular ligament injuries in the US. (Product-Related Announcements)
- Smith+Nephew launched the CENTRIO Platelet-Rich-Plasma System, enhancing its wound care portfolio and offering new treatment options for chronic wounds such as diabetic foot ulcers and pressure ulcers. (Product-Related Announcements)
Valuation Changes
- The consensus analyst price target has risen slightly from $14.23 to $14.37.
- The discount rate has increased moderately from 8.12% to 8.53%.
- Revenue growth projections have edged down from 5.47% to 5.41%.
- The net profit margin is expected to improve slightly, moving from 13.13% to 13.23%.
- The future P/E has increased marginally from 22.91x to 23.03x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.